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The ﬁrst case is about a man of 60 years old suﬀering of hypereosinophilic syndrome (HES) developed since 1998. He presented
chronic cough, insomnia, and negative parasitical test. We observed hypereosinophilia and ﬁbroblastic hyperplasia at the bone
m a r r o wb i o p s y .I n i t i a l l y ,h y d r o x y u r e aa n dα-interferon treatment failed. We proposed to him imatinib mesylate in May 2003.
The FIP1L1-PDGFRA gene was detected. The second case is about a man of 34 years old seen in March 2002. First investigation
concluded to CML. Progressively, eosinophil cells increased, and complications occurred as oedema syndrome, dyspnoea, and
parietal chronic endocarditic ﬁbrosis associated with pericarditis. In addition, a bowel obstruction happened and was cured by
surgery. Bcr-abl fusion was negative, and FIP1L1-PDGFRA gene was detected after and imatinib mesylate was given. Actually,
endocarditic ﬁbrosis decreased. The two patients are in haematologicaland cytogenetic remission. We concluded that clonal HES
is present in Africa, and imatinib mesylate is eﬀective.
1.Introduction
Hypereosinophilia (HE)isdeﬁned asa numberofeosinophil
granulocytes equal or greater than 0.5 × 109/liter or
500/mm3 of circulating blood [1]. It may result from numer-
o u sc a u s e sm o s to fw h i c hc a nb ei d e n t i ﬁ e db yt h r o u g h -
out patient’s history. In the majority of the cases, the
HE is secondary to an infection (mostly by a parasite),
an environmental allergen, or a medication. In few cases,
the HE is caused by a systemic disease such as a vasculitis.
In some situations no etiology is found to the HE even
after an exhaustive investigation. This type of eosiphilia
has been called hypereosinophilic syndrome (HES) or
Chusid’s syndrome since 1975 [2]. The criteria of WHO
classiﬁcation of chronic myeloproliferative diseases (2002)
for hypereosinophilic syndrome (HES) are the following:
eosinophilia >1.5 · 109/L for >6m o n t h sa n db ye n d -
organ damage, commonly endomyocardial ﬁbrosis, skin
lesions (angioedema, urticaria), thromboembolic disease,
pulmonary, lesions and central nervous system dysfunction.
Associated with polyclonal increased in immunoglobulins
including IgE, splenomegaly 40%, anemia 50%, and neu-
trophila with left shift frequent, platelets may be normal,
decreased, orincreased. Bone marrow hypercellularwith 25–
75% eosinophils with left shift [3].
Because of its poor prognosis [4], the challenge is to
make an early diagnosis. Even though Bain’s criteria are still
used to characterize the HES, recent progress in molecular
biology has brought a new light into the pathophysiology
and the treatment of this syndrome. The discovery of the
FIP1L1-PDGFRA [5] gene was an important step toward
the understanding of the disease. Diﬀerent subtypes of the
HES have been reported: the myeloproliferative type that
responds well to imatinib mesylate, the lymphoproliferative
subtype, and other syndromes with diﬀerent clinically and
with separate therapeutic orientations. Imatinib, an tyrosine
kinase inhibitor has successfully been used [6]t ot r e a t
the FIP1L1-PDGFRA positive hypereosinophilic syndromes
(HES). This subtype of HES has not been well documented
amongst the sub-Saharan African populations [7].
Wearereportinginthisstudy2casesofFIP1L1-PDGFRA
HES also known as clonal hypereosinophilic syndrome,2 ISRN Hematology
diagnosed in the clinical hematology unit of the Laboratory
services of the Campus teaching hospital of Lom´ ei nT o g o .
The objectives of this study are to describe the clinical
features of these 2 cases, to underline the diagnostic and
therapeutic diﬃculties giving our context, and to propose a
strategy to improve the diagnosis and treatment of patients
with clonal HES.
2.CaseReport
Case 1. Mr. A. Y. a 57-year-old Togolese man was referred to
the hematology unit in June 1999 for a chronic dry cough
and a hypereosinophilia. His past medical and family history
isnegative foratopicdiseases, diabetes,andhypertension. He
carries the AC hemoglobin type and mentioned a hepatitis A
infection in 1963 and two surgeries for a disc hernia.
Since December 1998, he has been having a dry cough,
refractory to cough suppressants. He was seen in cardiology
in May 1999, where a clinical wokup was signiﬁcant for
an hypereosinophilia of 4680/mm3.H i sc h e s tX - R a ya n d
chemistry panel including BUN, creatinine, and blood
glucose were negative. He was treated with antihistamine
and expectorant agents without any success. He was referred
to hematology in June 1999. He was well appearing with
no acute distress. His vital signs and physical exam were
within normal limits, mainly therewere nohepatosplenogaly
or lymphadenopathy. In addition to the tests performed
in cardiology, a marrow aspiration showed a granular
hyperplasia (82%) with a central hypereosinophilia of 37%.
Investigations to detect a possible parasite infection or an
atopic cause were negative.
On his request, Mr. A. Y. was transferred in November
1999 in Paris for further testing. The search for parasites
done in Lome was completed in Paris by series of serology
which was negative for trichinosis, toxocariasis, anguillilosis,
distomatosis, and ﬁlariasis. Tumor markers: ACE, CA-19.9,
PSA, and alpha fetoprotein were within the normal ranges
andthechestX-ray,EKGandechocardiogram, lungfunction
tests, and CT of the chest and the abdomen were normal.
The diagnosis of a myeloproliferative syndrome type
hypereosinophilia was adopted and Mr. A. Y. was started
on hydroxyurea one tablet of 500mg a day and allopurinol
300mg a day.
On 8th May 2000, the patient was seen back in Lome
with no change in the eosinophil count. It was agreed
to increase the hydroxyurea to 2 tablets of 500mg a day.
This was of no eﬀect on the eosinophil count but help to
normalize transiently the patient’s platelet count. Clinically,
the patient stated that the cough did not improve; in fact,
it was getting worse and was disturbing his sleep. On July
11th 2000, the hydroxyurea was changed to alter 2 or 3
tablets on days. In December 2000, the patient suﬀered
from an oral mycosis and was treated with mouthwashes
with a mixture of chlorexidine, amphotericin B and sodium
bicarbonate solution. He also complained of a pruritis, and
in January 2001, the patient had an onychomycosis due to
trichophyton rubrum and which was treated with terbinaﬁn,
hexomedine, and colchicine. Following the dermatologists
advice, the hydroxyurea was temporary discontinued. The
CBC of February and April 2001 showed an eosinophil
count of 7220 and 7880/mm3, respectively. The treatment
with hydroxyurea was not resumed, because it was not
eﬃcient before the therapeutic window. The patient general
condition did not improve; he was, in fact, loosing weigh
and also because the subsequent CBCs showed an anemia on
top of the hypereosinophilia. In February 2002, the patient
present with an elbow mass of the size of a gulf ball, ﬁrm,
associated with a right groin lymphadenopathy which was
biopsied and the biopsy report concluded to a nonspeciﬁc
adenitis.
The molecular study was negative for a T lymphocytes
clone; the marrow biopsy revealed an important ﬁbroblastic
hyperplasia and a diﬀuse increase of reticular network. A
treatment with Alpha interferon at 3IU three times a week
was started on August 02, 2002. The CBC and the liver
function tests were checked every week. After 2 weeks of
treatment, Mr. A. Y. noticed an improvement of the cough
but complained of tiredness. This treatment was continued
until October despite episodes of bodyache and insomnia.
A paper in Lancet has reported the eﬃcacy of Imatinib
mesylate in 5 patients with HES [8]. After discussing, we
proposed to our patient to try this medication. After one
month onimatinibat100mgtwicedaily,eosinophiliapassed
from 3956/mm3 to 78/mm3. The cough and the pruritis
improved, but because of the low WBC, an antibiotic
coverage was prescribed, and the imatinib discontinued.
After5months,thepatientreportedasteadyimprovementof
his symptoms and a better sleep quality.
An article in the NEJM in Marsh 2003 by Cools et al. [9]
reported that a tyrosine kinase which results from the fusion
of the PDGRA and FIP1L1 genes was the target of imitanib
in patients with HSE. In blood sample molecular analysis
of our patient, the PDGRA-FIP1L1 was found positive; this
ﬁtted our patient in the myeloproliferative PDGRA-FIP1L1
HES group as described by Cools et al. [9]. Six subsequent
evaluations for the fusion gene were negative, showing a
complete cytogenetic remission. The last evaluation for the
fusion gene 17 months was also negative. Actually, imatinib
was reduced to 1 tablet a day.
In conclusion, the diagnosis of PDGRA-FIP1L1 positive
hypereosinophilic syndrome myeloproliferative subtype was
made for this patient.
Case 2. Mr. M. K. a 32-year-old was seen in June 2002 for an
eosinophil count of 18348/mm3 on his annual checkup. His
pastmedicalhistoryisnegative,andhedeniedanyfamilyhis-
tory for atopy, has smoked a half pack of cigarettes a day for
10 years, and has stopped smoking since 2001. His vital signs
were within normal limit, and the clinical examination was
normal except a diminished breath sound on the left lung,
therewasnohepatosplenomegaly.The stoolsandurinestudy
for parasites as well as the serologic tests for the common
parasites were negative. A white blood count a week before
this visit demonstrated a leukocytosis of 205,400/mm3.A
marrow aspiration showed a granulocytic hyperplasia with
an important eosinophil content (19%). All these ﬁndings
were consistent with a chronic myelocytic leukemia (CML)ISRN Hematology 3
in the chronic phase. The patient was started on hydroxyurea
six tablets of 500mg and allopurinol 300mg a day. Soon
after staring these medications, the patient presented with
a pitting edema of the lower extremities, unsteady gait, a
right hypoacousia with hypoesthesia of the right side of
his face. The neurology and the ENT evaluations did not
ﬁnd any abnormalities. The initial treatment failed to bring
up a steady hematological remission, and a second marrow
aspiration on 01/03/2003 was still show features compatible
with the diagnosis of CML. We replaced hydroxyurea by
cytosine arabinoside known to be a more potent drug, 50mg
intramuscular injection. Since01/15/2003,the patient begun
to develop complications imputable to the hypereosiphilic
syndrome.
(i) An ascitis and hepatomegaly [10, 11] (on clinical
exam and also shown by the abdominal echography
of 01-27-2003),associated with edema and decreased
prothrombin time (PT) 38% (range 70%–100%).
These symptoms were ruled to be due to liver cirrho-
sis; therefore, the cytosine arabinoside was stopped
because of its potential of liver toxicity and toxic
encephalopathy. But because the white cell count
was increasing rapidly, hydroxyurea was resumed at
smaller doses. Meanwhile, a treatment with vitamin
K resulted in bringing the PT up to 70%.
(ii) A recurrent anemia [12] which warranted many
transfusionsofiso-groupandiso-Rhesusbloodunits.
(iii) A permanent shortness of breath and generalized
edema in March 2003. A cardiology workup discov-
ered a cardiomyopathy [13] with a small pericaditis
[14] and a signiﬁcantly impaired left ventricular
compliance. The previous liver abnormalities were
probably the result of a right heart failure. A treat-
ment with diuretics and vasodilators (furosemide,
spironolactone/altizide,and isosorbidedinitrate)was
added to hydroxyurea.
In addition to the above complications, the gait unsteadiness
and the right hypoacousia persisted.
Other investigations including a CT of the brain with
contrast, HIV and HBV tests, and kidney tests were normal.
The patienthad a bowel obstructionand was hospitalized for
surgical treatment for 4 months. Little before the surgery,
thorough investigations demonstrated that there was no
Philadelphia chromosome and made the diagnosis an HES
positive for the FIP1L1-PDGFRA fusion gene [9]. The
patient was started on imatinib on 11/06/2003, 2 tablets of
100mg a day. The CBC before treatment showed eosinophils
7891/mm3. After 3 weeks of treatment, a remission was
achieved as shown by the eosinophil count of 280/mm3.
Imatinib was then reduced to 100mg a day for the next 16
months and 6 days out of 7 for the following 12 months.
Thesedosagesweresuﬃcienttomaintain thegoodandstable
cytological response.
Actually, the patient is in a general good health. The
CBC revealed eosinophils at 128/mm3.T h ea b d o m i n a l
echography demonstrated that the hepatomegaly and the
distension of the sus-hepatic veins from the cardiac liver
were stable. The cardiac Doppler echography noted an
hemodynamic improvement despite the persistence of the
cardiomyopathy. The chest X-ray was normal. The FIP1L1-
PDGFRA fusion gene was still present in 3 subsequent
molecular biology testing performed in 2 years. The dosage
ofimitanib was, therefore,increased to200mgaday.The last
control showed that the FIP1L1-PDGFRA fusion gene was
negative. A possible resistance genes was not found.
In summary, an HES of the myeloproliferative type [15]
withFIP1L1-PDGFRAfusion genewastheﬁnal diagnosisfor
this patient.
3.Discussion
The analysis of these cases of hypereosinophilic syndrome
in 2 Black Africans brings up several points related to the
following:
(i) the deﬁnition and the disease terminology, which are
not deﬁnite and are evolving with the new scientiﬁc
developments,
(ii) theepidemiology,these2casesarereportsofadisease
rarely studied [7] or described in sub-Saharan Africa,
(iii) the diagnostic workup that requires tools not always
available in that part of the world,
(iv) lastly, to the treatment which has improved from
recent innovations.
3.1. Deﬁnitions and Nomenclatural Concepts. Our ﬁrst pa-
tient was initially seen in 1999. Essential hypereosinophilia
was exclusively deﬁned by Chusid’s criteria [2] formulated
since 1975. Based on these criteria a diagnosis of EHS
would have been satisfactory for that patient. In today’s
practice, because of the recent progress, the deﬁnition of
HES became disputable. Since the discovery of the FIP1L1-
PDGFRA fusion gene [9] in 2003, is it acceptable to call this
disease “essential” while that gene is strongly implicated in
the pathophysiology of that type ofhypereosinophilia? Many
authors have responded by the negative to that question
a n dh a v er e c o m m e n d e dt or e s e r v et h eu s eo ft h eq u a l i ﬁ e r s
idiopathic and essential for the cases for which no molec-
ular abnormalities [16] or other etiology were identiﬁed
[17]. Our patients had the FIP1L1-PDGFRA fusion gene,
and, therefore, their diagnosis was clonal hypereosinophilic
syndrome with molecular rearrangement PDGFRα.T h i s
exempliﬁes the diﬃculty to study heterogeneous groups of
idiopathic diseases for their pathophysiologic mechanisms
could be later identiﬁed. The most recent World Health
Organization classiﬁcation of the eosinophilic syndromes is
from 2002 [3]. This illustrates the delay between scientiﬁc
progress and their use in classifying diseases. Furthermore,
the Chusid’s criteria suggested that patients should have an
organ involvement, but Mr. A. Y. did not present any, and we
did not ﬁnd any objective pulmonary cause for his chronic
cough. His case is close to recent studies that found the
FIP1L1-PDGFRA fusion gene in patients who did not have
any systemic manifestations. It appears important that the
third criterion of Chusid’s syndrome be readjusted.4 ISRN Hematology
3.2. Epidemiologic Considerations. HES is a rare pathology
and cases with positive FIP1L1-PDGFRA are even more
uncommon based on the data available, the fusion gene is
found only in 17% to 56% of the time. Both of our patients
had the clonalHESand were the only 2cases diagnosed in 10
years (1998–2007)in the Laboratories service of the Campus
University Hospital. We did not any other description of the
disease in African medical literature [7]. One reason for this
is the lack of advanced investigative tools such as molecular
biology techniques to identify the FIP1L1-PDGFRA fusion
gene. Our study conﬁrms the putative notion that the clonal
HESdoesnothaveapredilectionforarace.Agreaternumber
of cases are needed before the rates of race repartition can be
eventually established. Our results are also in concordance
with the literature with regards to the sex ratio, and clonal
HES has a clear male predominance [18, 19]; from all the
cases reported, there is a male to female sex-ratio of 22:1.
This may be the result of a genetic diﬀerences or hormonal
inﬂuences on the break point on the chromosome 4 and
the expression of the fusion product. This type of inegality
has been also documented for PDGFRβ [20]. For the few
female cases of FIP1L1-PDGFRA, the systemic involvement
wasminimalifnotabsent[9].Thismayhaveplayaroleinthe
low prevalence of the disease in women, because they were
pauci- or asymptomatic. The disease has been reported in
broad range of age 16–72 years old. Our 2 patients were 32
and 56 years old, respectively. It seems that clonal HES is not
a disease of young adult only as suggested by some previous
data [2].
M. K., before been treated with imitanib, had a poor
prognosis because of the hypertrophic cardiomyopathy [21]
with congestive heart failure. His condition was greatly
improved with the treatment despite the fact that the my-
ocardial ﬁbrosis did not completely resolve. For the FIP1L1-
PDGFRA positive cases, the earlier the diagnosis is made
and the treatment started, the lower the mortality and
morbidity [22]. One element seems prejudicial in the case
of M. K., which is the persistence of the FIP1L1-PDGFRA
at subsequent molecular evaluations despite the imitanib
therapy. This is reported as a sign of poor prognosis [9,
22, 23], because there is a risk for transformation into an
eosinophilic leukemia which is a highly fatal disease. We
are going to investigate the possibility of the 2149 C→T
mutation of the PDGFRA sequence which was found in 3
patients with resistant to imitanib [9, 22].
3.3. The Diagnosis Approach. For our ﬁrst patient, the
possibility of an HES was considered after a thorough inves-
tigation including a test for the Philadelphia chromosome
[24] did not ﬁnd any causes for the eosinophilia. When the
FIP1L1-PDGFRA fusion gene was later described, we were
able to test our patient for it.
For the second patient (seen initially in June 2002), we
considered the possibility of a chronic myelocytic leukemia
(CML), which we could not rule out until the test for
the Philadelphia chromosome was performed in August
2003 by a french laboratory. The negative result made the
possibility of a clonal HES likely. The delay could have been
avoided if we had all the diagnostic tools available locally.
M. K. presented some neurological manifestations at the end
of 2002. He had an unsteadiness of the gait more while
walking. A neurology consult did not ﬁnd any pathology;
therefore, we considered this symptom to be related to the
hypereosinophilia [25,26];suchnervoussysteminvolvement
has been reported in 23% of the cases. M. K. also had an
eosinophilic cardiopathy [27] that was described in 29% of
the patients.
Both of our cases presented with a very high eosinophil
count (more than 7000/mm3) during the course of the
disease and were found positive for the FIP1L1-PDGFRA
gene. A study [28] of a cohort of 35 eosinophilia suggested
that patients with 3000 or more eosinophils/mm3 were more
likely to be positive for the FIP1L1-PDGFRA gene. The
same study showed that 100% of FIP1L1-PDGFRA positive
patients had a high level of serum tryptase, and that 85%
of patients with HES and an elevated serum tryptase were
FIP1L1-PDGFRA fusion gene positive. An elevated serum
tryptase seems a good sensitive and speciﬁc marker for
the presence of the FIP1L1-PDGFRA rearrangement and,
therefore, for clonal HES. We did not study the serum
tryptase in our patients. It has also been reported that
elevated serum vitamin B12, LDH, and leukocyte alkaline
phosphatase (LAP) are good criteria for myeloproliferative
type HES. This was not proven in our patients moreover A.
Y. had a normal LDHlevelin June 1999while the disease was
evolutive.
3.4. Treatment. Our patients, like 66% of the cases in
the literature, were treated with other drugs before ima-
tinib. With a dosage of 200mg a day of imatinib, both
patients responded well, and a signiﬁcant decrease in their
eosinophilia was achieved: 7891 to 280/mm3 in 22 days for
M. K. and 3956 to 78/mm3 in 37 days for A. Y. A dosage
of 100mg a day is now recommended for the treatment
of FIP1L1-PDGFRA positive eosinophilia. Some authors
proposed a trial with that drug even when the fusion gene
is not present, based on reports by Walz et al. [29]a n d
Salem et al. [30] of patients with FIP1L1-PDGFRA negative
HES that responded well to imatinib. This suggests that the
possibility of other cytogenetic abnormalities which are not
yet identiﬁed.
In both of our patients, the treatment with imatinib
resulted in also a signiﬁcant clinical improvement. M. K.
showed a remarkable amelioration of his cardiac function;
his cardiomyopathy which was well advanced before the
diagnosis of the clonal eosinophilia would have needed more
aggressive treatments even cardiac surgery back in the days
when imatinib was not used. In A. Y., the chronic cough and
the pruritus have totally subsided. Despite this globally good
outcomes, the persistence of the FIP1L1-PDGFRA fusion
gene, the elevated LDH, the high serum uric acid in M. K.
may be indicative of a persisting cellular proliferation. That
patient is being closely monitored because of concerns of a
transformation into eosinophilic leukemia.
T h em a i ni s s u ew i t ht h et r e a t m e n ti no u rc o n t e x to f
practice is its cost and availability. 60 tablets of 100mg costs
1287 Euros (800,000 francs CFA, more than 2 times theISRN Hematology 5
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Figure 1: Clinical workup of hypereosinophilia + positive results or outcome, − negative results or outcome, HES hypereosinophilic
syndrome PMH past medical history.
minimum annual salary in Togo) and the medication has to
beorderedfromabroad.Thisexplainthedelayinthestarting
ofthetreatment forbothofourpatientsandtheinterruption
of treatment in February 2007 for A. Y.
4.Conclusion
These 2 cases of clonal hypereosinophilic syndrome under-
lined the diﬃculties of the diagnostic workup of the many
diﬀerentials of hypereosinophilia in sub-Saharan Africa
[7]. Essential hypereosinophilic syndrome, an already rare
condition, is certainly under-diagnosed in Africa. This study
also allowed us to review the progress made in the diagnosis
and treatment of the disease. Our 2 patients beneﬁted from
the recent identiﬁcation of the FIP1L1-PDGFRA fusion gene
[9]asmajorroleplayerinthepathophysiologyofclonalHES,
by activation of a tyrosine kinase receptor. Imatinib mesylate
a tyrosine kinase inhitor which has been used since 2001 for
clonal HES was proven eﬃcient in both of our patients.
After analyzing our 2 cases and reviewing the medical
literature available, we are suggesting the diagnostic strategy
to guide the workup of hypereosinophilic syndromes as
presented in Figure 1.
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